ACADIA Pharmaceuticals Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 484.14M | 517.24M | 726.44M | 957.80M | 1.07B | 11.9% | |
| Cost of Revenue | (19.14M) | (10.17M) | (45.73M) | (81.84M) | (89.00M) | 8.7% | |
Gross Profit | 465.00M | 507.07M | 680.71M | 875.96M | 982.51M | 12.2% | |
| Operating Expenses | |||||||
| Research & Development | (239.41M) | (361.57M) | (351.62M) | (303.25M) | (328.80M) | 8.4% | |
| Selling, General & Administrative | (396.03M) | (369.09M) | (402.47M) | (488.43M) | (548.89M) | 12.4% | |
| Depreciation & Amortization | (3.34M) | (2.03M) | (5.55M) | (15.88M) | (11.76M) | -26.0% | |
Operating Income (EBIT) | -170.44M | -223.60M | -73.38M | 230.79M | 104.81M | -54.6% | |
| Non-Operating Items | |||||||
| Interest Income | 591.00K | 6.61M | 17.23M | 25.46M | 31.72M | 24.6% | |
| Interest Expense | — | — | — | — | — | — | |
| Other Income/Expenses (Net) | 2.92M | 10.15M | 22.34M | 27.28M | 34.09M | 25.0% | |
Income Before Tax | -167.52M | -213.44M | -51.04M | 258.07M | 138.90M | -46.2% | |
| Income Tax Expense | (351.00K) | (2.53M) | (10.25M) | (31.62M) | (252.10M) | -897.2% | |
Net Income | -167.87M | -215.97M | -61.29M | 226.45M | 391.00M | 72.7% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $-1 | $-1 | $-0 | $1 | $2 | 69.3% | |
| Weighted Avg Shares Outstanding | 160.49M | 161.68M | 163.82M | 165.72M | 169.34M | 2.2% | |
| Weighted Avg Shares Outstanding (Diluted) | 160.49M | 161.68M | 163.82M | 166.36M | 171.36M | 3.0% | |
EBITDA | -164.18M | -211.42M | -45.48M | 100.16M | 150.66M | 50.4% |
Explore ACAD
ACAD in the Healthcare
Mid Cap